Chart - NTI, page-16

Thanks mate, love the work. Yep I think I'm happy to keep fence sitting on this one and reassess in the new year - I still believe there is weakness to come on low volume and not expecting any material news flow until next quarter (i.e. outcome of PRE-IND meeting)...

All other "milestones" per AGM presentation in H1 2023 are commence trials or commence recruitment for trials... other than maybe some FOMO on trials starting, nothing actually reportable and material to move the SP until H2 2023..

JUST IMHO.. and my personal rationale for sitting and waiting while the poor market sentiment for biotech continues.

DYOR - GLTAH.